Metered Dose Inhalers Market Research Report Information By Product (Press Metered Dose Inhalers, Breath Actuated Metered Dose Inhalers), By Propellant Type (HFA 134A, HFA 227EA, HFA 152A), By Technology (Pulmonary Platform Technologies, Nasal Platform Technologies), By Indication (Asthma, COPD, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) Industry Forecast Till 2032
In 2023, the market for metered dose inhalers was estimated to be worth USD 15.8 billion. With a compound annual growth rate (CAGR) of 6.43% from 2024 to 2032, the sector is expected to increase from USD 17.1 billion in 2024 to USD 30.0 billion by 2032. Growing awareness and education, increased product releases by market participants, and the prevalence of respiratory illnesses are all contributing to the worldwide metered-dose inhaler market's expansion.
The global market for metered dosage inhalers (MDIs) is expanding due in large part to the growing availability of new MDI products. Technological innovations including better drug delivery systems and ergonomic designs brought about by these launches satisfy patient preferences for adherence and simplicity of usage. For a range of respiratory disorders, novel formulations and combinations provide additional therapeutic choices, enhancing patient outcomes and treatment efficacy. Pharmaceutical companies' competitive dynamics spur innovation and cost, giving patients and healthcare providers access to a greater selection of premium MDI solutions. Additionally, the market is growing due to specialized solutions for particular patient populations and purposeful market expansion into new regions, which makes MDI products essential for the global management of respiratory disorders.
Perspectives on Market SegmentsThe market for metered dose inhalers has been divided into two segments based on product: press-metered inhalers and breath-actuated inhalers.
The market for metered dose inhalers has been divided into three segments based on the kind of propellant: HFA 134a, HFA 227ea, and HFA-152a.
The market for metered dose inhalers has been divided into two segments based on technology: nasal platform technologies and pulmonary platform technologies.
The market for metered dose inhalers has been divided into segments based on indications, such as COPD and asthma.
The market for metered dose inhalers has been divided into three segments based on the distribution channel: hospital pharmacies, retail pharmacies, and online pharmacies.
Local PerspectivesIn 2023, North America held the biggest market share. However, over the 2024–2032 prediction period, Asia-Pacific is anticipated to develop at the greatest CAGR.
The market for metered dose inhalers in North America is expanding rapidly due to a favorable regulatory environment, rising healthcare demands, and technology breakthroughs. Furthermore, the market is driven by advanced healthcare infrastructure and significant research and development expenditures that have made it possible to create innovative Metered Dose Inhalers.
Europe, which is further divided into Germany, France, the United Kingdom, Italy, Spain, and the Rest of Europe, comes after the Americas. The European market for metered dose inhalers is characterized by a well-established healthcare infrastructure and rising healthcare costs.
Over the course of the forecast period, Asia-Pacific is anticipated to expand at the fastest rate and see substantial expansion due to several important variables. The need for advanced inhalers is being driven by the rapidly expanding healthcare infrastructure and rising investments in this sector in nations like China, India, and Japan.
Key PlayersAstraZeneca (UK), GSK PLC (UK), Organon (US), Cipla, Inc. (India), Lupin Pharmaceuticals, Inc. (India), Zydus Group (India), Teva Pharmaceutical Industries Ltd. (Israel), Viatris Inc. (US), Aristopharma Ltd. (Bangladesh), and Beximco Pharmaceuticals Limited (Bangladesh) are important players in the metered dose inhalers market.